不同病程精神分裂症患者临床对照分析

目的：探讨不同病程精神分裂症患者临床特征。方法：将203例住院精神分裂症患者按病程分成2组：研究组（病程〈5年）133例和对照组（病程≥5年）70例，采用自编《住院精神分裂症患者一般项目调查表》进行统计分析。结果：职业：对照组无业者比例较多见（P〈0．05）。文化：研究组初中多见；对照组高中及以上多见，2组比较有显著性差异（P〈0．05）。婚姻：对照组离异比例较多见（P〈0．05）。研究组病前生活事件、急性或亚急性起病较多见（P〈0．05或P〈0．01）。研究组关系妄想较多见，对照组自语自笑、阴性症状较多见（P〈0．05或P〈0．01）。2组间疗效差异不明显，对照组第二代抗精神病药物使用更广泛（P〈0．05）。结论：不同病程精神分裂症患者在文化、职业、婚姻、诱因、起病形式、临床表现等方面均有差别。第二代抗精神病药物有助于改善精神分裂症临床疗效。

The controlled analysis of the clinical feature of schizophrenia patients in various course of diseases

Objective: To explore the clinical feature of schizophrenia patients in various course of diseases.Methods: 228 schizophrenia in-patients were been divided two groups according to course of diseases: 133 cases had as research group(course of diseases less than 5 years) and 70 cases had as control group(course of diseases more than 5 years),Using self-edit ,we made statistics and analysis.Results: Occupation: the control group had more unemployed than that of research group(P<0.05).Education: the research group had more junior high school,the control group had more senior high school or more higher education,compared with the research group,the control group's education had significantly difference(P<0.05).Marriage: the control group had more divorcers(P<0.05).Compared with the control group,the research group had more prodromal life events,the types of onset were acute or sub-acute,which had significantly difference(P<0.05 or P<0.01).The symptoms of research group had more delusion of reference,the control group had more speech to themselves or no reasoning laugh,negative symptoms,which had significantly difference(P<0.05 or P<0.01).The curative effect between two groups had no difference,the control group took the second generation anti-psychosis drugs more extensive,which had significantly difference(P<0.05).Conclusions: Schizophrenia patients in various course of diseases had difference education,occupation,marriage,pathogenesis,types of onset and clinical features.The second generation anti-psychosis drugs are good for improving the curative effect of schizophrenia patients.